ライフサイエンスコーパス: sudden cardiac death

1 iac events (syncope, aborted cardiac arrest, sudden cardiac death).

2 n 64 families (230 relatives, 80 unexplained sudden cardiac death).

3 lications of heart disease and can result in sudden cardiac death.

4 eading cause of mortality on hemodialysis is sudden cardiac death.

5 rs are indicated for prevention of secondary sudden cardiac death.

6 h risk indicator for cardiac arrhythmias and sudden cardiac death.

7 is a risk factor for cardiac arrhythmias and sudden cardiac death.

8 lock, atrial or ventricular arrhythmias, and sudden cardiac death.

9 evation myocardial infarction and 6 (17%) as sudden cardiac death.

10 for a group known to have elevated rates of sudden cardiac death.

11 e to ischemia-associated QT prolongation and sudden cardiac death.

12 of lesions lead to heart attack, stroke, or sudden cardiac death.

13 d by cardiac hypertrophy, heart failure, and sudden cardiac death.

14 and the mechanisms of arrhythmias leading to sudden cardiac death.

15 r ICD implantation for primary prevention of sudden cardiac death.

16 inherited cardiac disorders associated with sudden cardiac death.

17 ventricular arrhythmias, cardiac arrest, and sudden cardiac death.

18 to advance the science and clinical care of sudden cardiac death.

19 for studying arrhythmic disorders leading to sudden cardiac death.

20 interval (Tp-e) is an independent marker of sudden cardiac death.

21 nsive research, as it increases the risk for sudden cardiac death.

22 to model and study disorders associated with sudden cardiac death.

23 effective new therapy in patients at risk of sudden cardiac death.

24 nt affects subsequent risk for mortality and sudden cardiac death.

25 brillator is implanted to reduce the risk of sudden cardiac death.

26 ated disc proteins and ultimately results in sudden cardiac death.

27 he quality of life and increase the risk for sudden cardiac death.

28 and another 11 patients suffered an aborted sudden cardiac death.

29 e blood pressure response, a risk factor for sudden cardiac death.

30 rvive have increased risk of arrhythmias and sudden cardiac death.

31 able cardioverter defibrillator therapy, and sudden cardiac death.

32 oth associated with cardiovascular death and sudden cardiac death.

33 malformation associated with a high risk of sudden cardiac death.

34 adverse cardiovascular outcomes, especially sudden cardiac death.

35 romes, cardiac arrhythmias, syncope, or even sudden cardiac death.

36 e a precursor of ventricular arrhythmias and sudden cardiac death.

37 s that can degenerate into heart failure and sudden cardiac death.

38 tion of an ICD for the primary prevention of sudden cardiac death.

39 main goal of treatment is the prevention of sudden cardiac death.

40 left ventricular dysfunction, or potentially sudden cardiac death.

41 unction can help select patients at risk for sudden cardiac death.

42 of cardiac death, onset of CHF, and aborted sudden cardiac death.

43 ng heart failure, myocardial infarction, and sudden cardiac death.

44 ardiovascular mortality from arrhythmias and sudden cardiac death.

45 lar cardiomyopathy (ARVC) is associated with sudden cardiac death.

46 Atrial fibrillation (AF) is associated with sudden cardiac death.

47 t ICD implantation for primary prevention of sudden cardiac death.

48 and are prone to ventricular arrhythmias and sudden cardiac death.

49 n results in devastating outcomes, including sudden cardiac death.

50 e propensity for ventricular arrhythmias and sudden cardiac death.

51 pathogenesis of ventricular arrhythmias and sudden cardiac death.

52 ed to pump failure and 14 were attributed to sudden cardiac death.

53 ycardia, with 5 presenting with resuscitated sudden cardiac death.

54 diomyopathy, congenital heart failure and/or sudden cardiac death.

55 n HFpEF, which in turn predisposes to VA and sudden cardiac death.

56 S2), a heart rhythm disorder associated with sudden cardiac death.

57 ias, leading to ventricular fibrillation and sudden cardiac death.

58 riggered syncope, aborted cardiac arrest, or sudden cardiac death.

59 ricular tachycardia (VT) is a major cause of sudden cardiac death.

60 rdiac hypertrophy are major risk factors for sudden cardiac death.

61 table cardioverter-defibrillator shocks, and sudden cardiac death.

62 All-cause mortality and sudden cardiac death.

63 ricular arrhythmias and an increased risk of sudden cardiac death.

64 e been linked to ventricular arrhythmias and sudden cardiac death.

65 achycardia, aborted sudden cardiac death, or sudden cardiac death.

66 ical interventions with potential to prevent sudden cardiac death.

67 osis (CS) may manifest as arrhythmia or even sudden cardiac death.

68 -myocyte junction and are a leading cause of sudden cardiac death.

69 ading to impaired mechanical contraction and sudden cardiac death.

70 tor (ICD) in the treatment and prevention of sudden cardiac death.

71 ardial repolarization and are susceptible to sudden cardiac death.

72 roke, invasive cardiovascular procedures, or sudden cardiac death.

73 n associated with delayed repolarization and sudden cardiac death.

74 ication and treatment of patients at risk of sudden cardiac death.

75 h risk indicator for cardiac arrhythmias and sudden cardiac death.

76 den cardiac death as compared with explained sudden cardiac death.

77 with a striking frequency of arrhythmias and sudden cardiac deaths.

78 from cardiovascular causes, of which 15 were sudden cardiac deaths.

79 age had the highest incidence of unexplained sudden cardiac death (0.8 cases per 100,000 persons per

80 .89]), and not associated with arrhythmia or sudden cardiac death (0.95 [0.76-1.19]).

81 al]) of cardiac death (1.45 [1.24 to 1.69]), sudden cardiac death [1.70 (1.34 to 2.15)], first cardio

82 strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72-20.42% and 16.

83 20%; P<0.001), as well as family history of sudden cardiac death (17% versus 7%; P=0.002).

84 35 years of age had the highest incidence of sudden cardiac death (3.2 cases per 100,000 persons per

85 median follow-up, 66 (22%) patients died (13 sudden cardiac death; 33 with LVEF >35%).

86 ventricular arrhythmias (82%); and frequent sudden cardiac death (40 cases in 21 of 28 families).

87 Unexplained sudden cardiac death (40% of cases) was the predominant

88 hronic heart failure (42%), pneumonia (10%), sudden-cardiac death (7%), cancer (6%), and hemorrhage (

89 ump failure (5% vs. 18%; P=0.03), but not of sudden cardiac death (9% vs. 16%; P=0.39).

90 cturally normal heart carries a low risk for sudden cardiac death; accordingly, there is typically no

91 ilure (aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to 11.2) o

92 romycin increases risk of cardiovascular and sudden cardiac death, although the underlying mechanisms

93 However, the recognition of the risk for sudden cardiac death among basketball players is challen

94 hic, and autopsy information on all cases of sudden cardiac death among children and young adults 1 t

95 Sudden cardiac death among children and young adults is

96 ulation-based, clinical and genetic study of sudden cardiac death among children and young adults.

97 ed the identification of a possible cause of sudden cardiac death among children and young adults.

98 in reducing risk of all-cause mortality and sudden cardiac death among patients with an EF </=35% at

99 muM) had a 4-fold higher risk of cardiac or sudden cardiac death and a 2-fold higher risk of any-cau

100 a direct role for CAP2 and actin dynamics in sudden cardiac death and cardiac conduction disease.

101 The secondary outcomes were sudden cardiac death and cardiovascular death.

102 of myocardial fibrosis predicts both risk of sudden cardiac death and likelihood of LV functional rec

103 myectomy with long-term follow-up, (aborted) sudden cardiac death and mortality rates were found to b

104 Modes of death were divided into sudden cardiac death and nonsudden death and compared be

105 ed with significant complications, including sudden cardiac death and premature atherosclerosis, abse

106 ons for prediction and prevention of SCA and sudden cardiac death and provides justification for a re

107 mortality is high in ESRD, partly driven by sudden cardiac death and recurrent heart failure due to

108 ations: For this review, we analyzed data on sudden cardiac death and SCA available from population s

109 Familial history of sudden cardiac death and ST-segment depression associate

110 (AF) predispose to ventricular arrhythmias, sudden cardiac death and stroke.

111 ciated with a transient elevation in risk of sudden cardiac death and that appropriate training subst

112 The primary focus has been sudden cardiac death and the utility of screening with o

113 ultivariate Cox regression analysis, aborted sudden cardiac death and VA inducibility on electrophysi

114 nt of our analyses, whereas the composite of sudden cardiac death and ventricular tachycardia requiri

115 fibrillation (VF), the most common cause of sudden cardiac death and whether this association is ind

116 There were no sudden cardiac deaths and no deaths related to liver fai

117 fatal and nonfatal myocardial infarction and sudden cardiac death), and harms.

118 drome, the most common cause of drug-induced sudden cardiac death, and a common reason for drug restr

119 sease severity expression, high-incidence of sudden cardiac death, and absence of skeletal myopathy o

120 all-cause mortality, heart transplantation, sudden cardiac death, and appropriate implantable cardio

121 pically required due to an elevated risk for sudden cardiac death, and catheter ablation can be used

122 nsible for a complex phenotype of LQTS, HCM, sudden cardiac death, and congenital heart defects.

123 ar tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are

124 at risk for hypertrophic cardiomyopathy and sudden cardiac death, and those who test positive are to

125 ter defibrillators for primary prevention of sudden cardiac death are less likely to experience susta

126 nce of sustained ventricular arrhythmias and sudden cardiac death are lower in women than in men.

127 Nevertheless, arrhythmic events and sudden cardiac death are not negligible.

128 (AF), sustained ventricular arrhythmias, and sudden cardiac death are recognized.

129 s worse compared with other etiologies, with sudden cardiac death as an important mode of death.

130 re independently associated with unexplained sudden cardiac death as compared with explained sudden c

131 There has been a decrease in aborted sudden cardiac death as the first manifestation of the d

132 based on an estimate of a patient's risk of sudden cardiac death, as well as their preferences and v

133 These sudden cardiac deaths associated with Lyme carditis occu

134 icologic and histologic studies (unexplained sudden cardiac death), at least 59 cardiac genes were an

135 ecutive families who experienced unexplained sudden cardiac death before 45 years of age were include

136 ntly associated with the presence of aborted sudden cardiac death but also occurred in 13% of asympto

137 as emerged as a novel tool for prevention of sudden cardiac death, but clinical performance data for

138 Ds) improve survival in patients at risk for sudden cardiac death, but complications remain an import

139 recommended at autopsy in suspected cases of sudden cardiac death, but data on the role of nonselecti

140 cardiomyopathy (ARVC) is a leading cause of sudden cardiac death, but its progression over time and

141 hERG) ion channel, have been associated with sudden cardiac death, but only a subset of these variant

142 A portion of sudden cardiac deaths can be attributed to structural he

143 A locus that confers a risk for sudden cardiac death, cardiac conduction disease, and a

144 ine receptor-2 (RyR2) gene in both SUDEP and sudden cardiac death cases linked to catecholaminergic p

145 Although rare, sudden cardiac death caused by Lyme disease might be an

146 Hypertension is a risk factor for sudden cardiac death caused by ventricular tachycardia a

147 is review article, part of the Compendium on Sudden Cardiac Death, discusses the major issues related

148 8 deletion (Ppp1r13l(Delta8/Delta8)) die of sudden cardiac death, displaying features of ARVC.

149 orphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodi

150 Sudden cardiac death during follow-up occurred more freq

151 Overall, 14 of 50 patients suffered a sudden cardiac death during follow-up, with a cumulative

152 tients, both in the placebo group, died from sudden cardiac death during follow-up.

153 ular ejection fraction for the prediction of sudden cardiac death events.

154 recipitates ventricular tachyarrhythmias and sudden cardiac death except in Brugada and J-wave syndro

155 Sudden cardiac death (fatal or aborted) was the primary

156 For sudden cardiac death, FHSD, nsVT, and obstruction showed

157 Strategies for prevention of sudden cardiac death focus on severe left ventricular (L

158 There were 2156 cases of sudden cardiac death from across the United Kingdom refe

159 ound that the mice developed CCD, leading to sudden cardiac death from complete heart block, but no l

160 Risk stratification in the context of sudden cardiac death has been acknowledged as one of the

161 Although sudden cardiac death has been broadly studied, little is

162 ; 95% confidence interval, 1.31 to 6.82) and sudden cardiac death (hazard ratio, 4.52; 95% confidence

163 -10.50]; P<0.001) and higher rate of aborted sudden cardiac death (hazard ratio, 8.31 [1.66-41.55]; P

164 Some patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrilla

165 tes conferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hospitalizatio

166 ; 95% confidence interval, 1.12 to 2.81) and sudden cardiac death (HR, 2.41; 95% confidence interval,

167 id not receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in

168 The pathogenesis of sudden cardiac death in college athletes has not been de

169 tive analysis examined data collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT),

170 eatment Evaluation Trial (DEFINITE), and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

171 In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) population,

172 In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), a pre-spec

173 ormance was assessed in the SCD-HeFT cohort (Sudden Cardiac Death in Heart Failure Trial; n=2521).

174 s), the first line of therapy for preventing sudden cardiac death in high-risk patients, deliver appr

175 t is the most common finding after suspected sudden cardiac death in NCAA athletes.

176 s generally and patients at risk for SCA and sudden cardiac death in particular is limited by the div

177 rter defibrillator (ICD) therapy may prevent sudden cardiac death in patients with ARVD/C.

178 tor (ICD) is the standard therapy to prevent sudden cardiac death in patients with coronary artery di

179 provide only modest risk stratification for sudden cardiac death in patients with nonischemic dilate

180 The causes of increased risk of sudden cardiac death in schizophrenia are not resolved.

181 bility is a well-established risk factor for sudden cardiac death in survivors of acute myocardial in

182 Current risk stratification strategies for sudden cardiac death in the heart failure patient are no

183 nraveling genetic factors that predispose to sudden cardiac death in the setting of sequela of corona

184 Although sudden cardiac death in the young is rare, it frequently

185 diomyopathy (ARVC) is a significant cause of sudden cardiac death in the young.

186 f ICD implantation for primary prevention of sudden cardiac death in this patient group is low.

187 the patients, illustrating the high risk for sudden cardiac death in this population.

188 fied in 31 of 113 cases (27%) of unexplained sudden cardiac death in which genetic testing was perfor

189 It is also the most common cause of sudden cardiac death in young adults and a major cause o

190 ycardia (CPVT) represent treatable causes of sudden cardiac death in young adults and children.

191 individuals, and it is the leading cause of sudden cardiac death in young adults.

192 rhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients.

193 g arrhythmic events (LAE) (cardiac arrest or sudden cardiac death) in SQTS patients.

194 associates with cardiovascular mortality and sudden cardiac death independent of traditional risk fac

195 Sudden cardiac death is a common cause of death in patie

196 in the therapy of underlying heart disease, sudden cardiac death is a major cause of death worldwide

197 Sudden cardiac death is a major contributor to mortality

198 Sudden cardiac death is common in humans with restrictiv

199 -defibrillators (ICDs) for the prevention of sudden cardiac death is continuing to increase.

200 cardioverter defibrillator for prevention of sudden cardiac death is deferred for 90 days after coron

201 The incidence of sudden cardiac death is higher in US basketball players

202 Although the risk of sudden cardiac death is highest in the first month after

203 Sudden cardiac death kills 180,000 to 450,000 Americans

204 ion has identified that long QT syndrome and sudden cardiac death may occur as a result of a deletion

205 Sudden cardiac death occurred in 24 patients (4.3%) in t

206 13% of the families in which an unexplained sudden cardiac death occurred.

207 Sudden cardiac death occurs in a broad spectrum of cardi

208 l, 0.92-0.98; P=0.004) and family history of sudden cardiac death (odds ratio, 3.5; 95% confidence in

209 Sudden cardiac death often involves arrhythmias triggere

210 ify the sizeable subset at increased risk of sudden cardiac death or disease progression and heart fa

211 athy (AC) is a hereditary disease leading to sudden cardiac death or heart failure.

212 of heart failure or transplantation but not sudden cardiac death or implantable cardioverter defibri

213 ent was an arrhythmic composite end point of sudden cardiac death or nonfatal episode of ventricular

214 Patients with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for ve

215 t failure (HR, 1.48; 95% CI, 1.43-1.53), and sudden cardiac death or ventricular arrhythmia (HR, 1.65

216 rdial infarction, heart failure, stroke, and sudden cardiac death or ventricular arrhythmia.

217 farction, readmission for heart failure, and sudden cardiac death or ventricular arrhythmia.

218 The composite incidence of sudden cardiac death or ventricular tachycardia was 41%

219 for major arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asy

220 d with a history of ventricular arrhythmias, sudden cardiac death, or implantable cardioverter-defibr

221 , sustained ventricular tachycardia, aborted sudden cardiac death, or sudden cardiac death.

222 inheritance of the condition and the risk of sudden cardiac death, other family members are tested fo

223 tes of malignant ventricular arrhythmias and sudden cardiac death (p = 0.593).

224 However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and yo

225 rited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and

226 Gene delivery of Ang-(1-9) reduced sudden cardiac death post-MI.

227 ventricular (LV) dysfunction, although most sudden cardiac death postmyocardial infarction occurs in

228 efibrillators (ICDs) are a standard means of sudden cardiac death prevention.

229 hods to identify patients at higher risk for sudden cardiac death, primarily left ventricular ejectio

230 ibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patien

231 ars, whereas for patients >70 years old, the sudden cardiac death rate was 1.6 (95% CI, 0.8-3.2) and

232 For patients </=70 years old, the sudden cardiac death rate was 1.8 (95% CI, 1.3-2.5) and

233 , 0.66; 95% confidence interval, 0.50-0.87), sudden cardiac death (relative hazard, 0.57; 95% confide

234 as a base case, the complex epidemiology of sudden cardiac death risk and the substantial new fundin

235 Using sudden cardiac death risk as a base case, the complex ep

236 l decision is whether a particular patient's sudden cardiac death risk is sufficient to justify place

237 The model is developed for the case of sudden cardiac death risk, but the concept is applicable

238 imed to establish (1) whether ECG markers of sudden cardiac death risk, in particular Brugada-ECG pat

239 In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevatio

240 risk factor for ventricular arrhythmias and sudden cardiac death (SCD) and could indicate the presen

241 Although cardio-vascular incidents and sudden cardiac death (SCD) are among the leading causes

242 Sudden cardiac arrest and sudden cardiac death (SCD) are terms often used intercha

243 lators (ICDs) used for primary prevention of sudden cardiac death (SCD) concluded that ICDs are less

244 s study sought to determine the incidence of sudden cardiac death (SCD) during Minnesota State High S

245 may present with ventricular arrhythmias and sudden cardiac death (SCD) even in the absence of hemody

246 Sudden cardiac death (SCD) events (including appropriate

247 Most sudden cardiac death (SCD) events occur in the general p

248 Sudden cardiac death (SCD) from arrhythmias is a leading

249 c death from advanced heart failure (HF) and sudden cardiac death (SCD) in a large patient cohort und

250 Although the occurrence of sudden cardiac death (SCD) in a young person is a rare e

251 Sudden cardiac death (SCD) in an athlete is a rare yet h

252 Accurate knowledge of causes of sudden cardiac death (SCD) in athletes and its precipita

253 The incidence and cause of sudden cardiac death (SCD) in athletes is debated with h

254 lectrocardiographic parameters as markers of sudden cardiac death (SCD) in BrS.

255 The risk of sudden cardiac death (SCD) in patients with heart failur

256 cardiomyopathy for the primary prevention of sudden cardiac death (SCD) in those with a left ventricu

257 ranean and DASH dietary patterns and risk of sudden cardiac death (SCD) in women.

258 Sudden cardiac death (SCD) is a devastating event afflic

259 Sudden cardiac death (SCD) is a devastating event in the

260 Sudden cardiac death (SCD) is a leading cause of death i

261 Sudden cardiac death (SCD) is a major cause of mortality

262 Sudden cardiac death (SCD) is a major source of mortalit

263 Knowledge of the burden and causes of sudden cardiac death (SCD) is sparse in persons aged<50

264 Sudden cardiac death (SCD) is the leading cause of morta

265 Sudden cardiac death (SCD) is the leading global cause o

266 Sudden cardiac death (SCD) is the most devastating manif

267 Arrhythmic sudden cardiac death (SCD) may be caused by ventricular

268 ospitalization, and a composite end point of sudden cardiac death (SCD) or aborted SCD.

269 tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public he

270 assessed the echocardiographic predictors of sudden cardiac death (SCD) within 2 population-based coh

271 l heart disease carries an elevated risk for sudden cardiac death (SCD), and implantable cardioverter

272 use a new clinical risk prediction model for sudden cardiac death (SCD), based on the HCM Risk-SCD st

273 dren with cardiomyopathy (CM) are at risk of sudden cardiac death (SCD), but the incidence and risk f

274 ythmia syndromes are at an increased risk of sudden cardiac death (SCD).

275 pertrophic cardiomyopathy is associated with sudden cardiac death (SCD).

276 has assessed whether it is a risk factor for sudden cardiac death (SCD).

277 dentified in approximately 80% of victims of sudden cardiac death (SCD).

278 ntricular arrhythmia is the leading cause of sudden cardiac death (SCD).

279 in an animal model of heart failure (HF) and sudden cardiac death (SCD).

280 ide screening program for conditions causing sudden cardiac death (SCD).

281 gation of the QT interval is associated with sudden cardiac death (SCD).

282 ament protein leads to an increased risk for sudden cardiac death (SCD).

283 atic individuals account for the majority of sudden cardiac deaths (SCDs).

284 leads to the pandemics of heart failure and sudden cardiac death, thus calling for a reappraisal of

285 Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator

286 hanical circulatory support/transplantation, sudden cardiac death, vascular outcomes in coarctation o

287 rdiac death, heart transplantation, survived sudden cardiac death, ventricular fibrillation, sustaine

288 Sudden cardiac death was not observed in young pigs; how

289 Sudden cardiac death was recorded in five patients, and

290 rillators (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago

291 The most common explained causes of sudden cardiac death were coronary artery disease (24% o

292 A total of 45 cases of sudden cardiac death were identified in National Collegi

293 A total of 490 cases of sudden cardiac death were identified.

294 illator therapy, survived cardiac arrest, or sudden cardiac death) were studied.

295 defined as stroke, myocardial infarction, or sudden cardiac death, were assessed prospectively over a

296 CM) or ischemic cardiomyopathy (ICM) against sudden cardiac death while awaiting re-evaluation of car

297 Here, we review the genetic basis of sudden cardiac death with a focus on the current knowled

298 ics of victims and circumstances surrounding sudden cardiac death with a normal heart (ie, sudden arr

299 After sudden cardiac death with negative autopsy, clinical scr

300 Familial evaluation after sudden cardiac deaths with autopsy findings of uncertain